Efficacy and predictive factors of cyclosporine A in alopecia areata: a systematic review with meta-analysis

References

• Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42(4):549–566.
   PubMed Web of Science ®Google Scholar
• Ruiz-Doblado S, Carrizosa A, García-Hernández MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434–437.
   PubMed Web of Science ®Google Scholar
• Sellami R, Masmoudi J, Ouali U, et al. The relationship between alopecia areata and alexithymia, anxiety and depression: a case-control study. Indian J Dermatol. 2014;59(4):421.
   PubMed Web of Science ®Google Scholar
• Colon EA, Popkin MK, Callies AL, et al. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry. 1991;32(3):245–251.
   PubMed Web of Science ®Google Scholar
• Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–926.
   PubMed Web of Science ®Google Scholar
• Mukherjee N, Morrell DS, Duvic M, et al. Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study. BMC Dermatol. 2009;9:11.
   PubMedGoogle Scholar
• Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23(2):227–243.
   PubMed Web of Science ®Google Scholar
• Dombrowski NC, Bergfeld WF. Alopecia areata: what to expect from current treatments. Cleveland Clin J Med. 2005;72(9):758–768.
   PubMed Web of Science ®Google Scholar
• Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163–170.
   PubMed Web of Science ®Google Scholar
• Sternthal MB, Murphy SJ, George J, et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103(4):937–943.
   PubMed Web of Science ®Google Scholar
• Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011;4:107–115.
   PubMedGoogle Scholar
• Lai VWY, Chen G, Gin D, et al. Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019;81(3):694–701.
   PubMed Web of Science ®Google Scholar
• Jang YH, Kim SL, Lee KC, et al. A comparative study of oral cyclosporine and betamethasone minipulse therapy in the treatment of alopecia areata. Ann Dermatol. 2016;28(5):569–574.
   PubMed Web of Science ®Google Scholar
• Yeo IK, Ko EJ, No YA, et al. Comparison of high-dose corticosteroid pulse therapy and combination therapy using oral cyclosporine with low-dose corticosteroid in severe alopecia areata. Ann Dermatol. 2015;27(6):676–681.
   PubMed Web of Science ®Google Scholar
• Constantopoulos A, Tsoumacas C, Tsivitanidou T. Cyclosporine in severe alopecia areata in children. J Eur Acad Dermatol Venerol. 1996;7(2):190–192.
   Google Scholar
• Lee JR, Choi SY, Han GS. The combination therapy of cyclosporine and methylprednisolone on severe alopecia areata: 3-year follow-up study. Int J Trichol. 2009;1(1):1.
   PubMedGoogle Scholar
• Lee D, Oh DJ, Kim JW, et al. Treatment of severe alopecia areata: combination therapy using systemic cyclosporine a with low dose corticosteroids. Ann Dermatol. 2008;20(4):172–178.
   PubMed Web of Science ®Google Scholar
• Shaheedi-Dadras M, Karami A, Mollaei F, et al. The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. Arch Iran Med. 2008;11(1):90–93.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Min SU, Park KY, et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat. 2008;19(4):216–220.
   PubMed Web of Science ®Google Scholar
• Rallis E, Nasiopoulou A, Kouskoukis C, et al. Oral administration of cyclosporin A in patients with severe alopecia areata. Int J Tissue React. 2005;27(3):107–110.
   PubMedGoogle Scholar
• Ferrando J, Grimalt R. Partial response of severe alopecia areata to cyclosporine A. Dermatology. 1999;199(1):67–69.
   PubMed Web of Science ®Google Scholar
• Shapiro J, Lui H, Tron V, et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1997;36(1):114–117.
   PubMed Web of Science ®Google Scholar
• Teshima H, Urabe A, Irie M, et al. Alopecia universalis treated with oral cyclosporine A and prednisolone: immunologic studies. Int J Dermatol. 1992;31(7):513–516.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ellis CN, Cooper KD, et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol. 1990;22(2):242–250.
   PubMed Web of Science ®Google Scholar
• Gadzhigoroeva A. Optimization of severe forms’ treatment of alopecia areata using corticosteroids. J Investig Dermatol. 2013;133(5):1392.
   Web of Science ®Google Scholar
• Açıkgöz G, Calışkan E, Tunca M, et al. The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol. 2014;33(3):247–252.
   PubMed Web of Science ®Google Scholar
• Shin JW, Huh CH, Kim MW, et al. Comparison of the Treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Derm Venereol. 2019;99(1):41–46.
   PubMed Web of Science ®Google Scholar
• Lai VWY, Chen G, Gin D, et al. Systemic treatments for alopecia areata: a systematic review. Australas J Dermatol. 2019;60(1):e1–e13.
   PubMed Web of Science ®Google Scholar
• Nowaczyk J, Makowska K, Rakowska A, et al. Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata: a systematic review. Dermatol Ther. 2020;10(3):387–399.
   Web of Science ®Google Scholar
• Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–856.
   PubMed Web of Science ®Google Scholar
• Ferron GM, Pyszczynski NA, Jusko WJ. Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays. Transplantation. 1998;65(9):1203–1209.
   PubMed Web of Science ®Google Scholar
• Phillips MA, Graves JE, Nunley JR. Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine. J Am Acad Dermatol. 2005;53(5):S252–S255.
   PubMed Web of Science ®Google Scholar
• Paus R. Therapeutic strategies for treating hair loss. Drug Discov Today Ther Strateg. 2006;3(1):101–110.
   Google Scholar
• Gafter-Gvili A, Kalechman Y, Sredni B, et al. Cyclosporin A-induced hair growth in mice is associated with inhibition of hair follicle regression. Arch Dermatol Res. 2004;296(6):265–269.
   PubMed Web of Science ®Google Scholar
• Paus R, Handjiski B, Czarnetzki BM, et al. A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A. J Invest Dermatol. 1994;103(2):143–147.
   PubMed Web of Science ®Google Scholar
• Moreno JC, Ocana MS, Velez A. Cyclosporin A and alopecia areata. J Eur Acad Dermatol Venereol. 2002;16(4):417–418.
   PubMed Web of Science ®Google Scholar
• Roger D, Charnes JP, Bonnetblanc JM. Alopecia areata occurring in a patient receiving systemic cyclosporin A. Acta Derm Venereol. 1994;74:154.
   PubMed Web of Science ®Google Scholar
• Davies MG, Bowers PW. Alopecia areata arising in patients receiving cyclosporin immunosupresssion. Br J Dermatol. 2006;132(5):835–836.
   Google Scholar
• Lee D, Hong SK, Park SW, et al. Serum levels of IL-18 and sIL-2R in patients with alopecia areata receiving combined therapy with oral cyclosporine and steroids. Exp Dermatol. 2010;19(2):145–147.
   PubMed Web of Science ®Google Scholar
• Lai VWY, Chen G, Sinclair R. Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. J Dermatolog Treat. 2021;32(2):250–257.
   PubMed Web of Science ®Google Scholar
• Hordinsky MK. Treatment of alopecia areata: “what is new on the horizon?”. Dermatol Ther. 2011;24(3):364–368.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594–1609.
   PubMed Web of Science ®Google Scholar